TrialAnnals of oncology : official journal of the European Society for Medical Oncology2018

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.

S Novello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.